{"filings":[{"id":1194597,"accession_number":"0001104659-26-076352","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2026-06-22T20:01:26+00:00","items":["5.07"],"status":"ready","headline":"ArriVent BioPharma announces 2026 annual meeting voting results; directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected James Healy, John Hohneker, and Stuart Lutzker as Class II directors for three-year terms.","Healy received 18,058,285 votes for; Hohneker 28,043,164; Lutzker 29,495,923; broker non-votes 3,832,858 each.","Ratification of PricewaterhouseCoopers LLP as auditor for FY 2026 passed with 33,411,773 votes for, 829 against.","Quorum of 33,418,793 shares (72.07% of eligible) was present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":14363,"accession_number":"0001104659-26-058706","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2026-05-11T20:43:06+00:00","items":["8.01","9.01"],"status":"ready","headline":"ArriVent BioPharma expands at-the-market equity program by up to $250M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on May 11, 2026 to sell up to $250,000,000 of common stock via ATM.","Jefferies LLC named as sales agent under existing Open Market Sale Agreement dated Feb 3, 2025.","Proceeds will be used for general corporate purposes; no specific use disclosed.","Offering is made under automatic shelf registration statement (Form S-3ASR, File 333-284661)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12927,"accession_number":"0001104659-26-058638","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2026-05-11T20:05:49+00:00","items":["2.02","9.01"],"status":"ready","headline":"ArriVent Q1 net loss $43.3M; cash $326.4M; Phase 3 firmonertinib data mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.3M for Q1 2026 versus $64.4M in Q1 2025; R&D expenses $37.6M (down 39% YoY).","Cash and investments $326.4M as of March 31, 2026, expected to fund operations into 4Q 2027.","Topline Phase 3 FURVENT data for firmonertinib in first-line EGFR exon 20 insertion NSCLC expected mid-2026.","FDA IND clearance for ARR-002 (MUC16/NaPi2b dual-target tetravalent ADC) for ovarian/endometrial cancers; first patient dosing in 2H 2026.","ARR-217 (CDH17 ADC) first patient dosed March 2026; dose escalation ongoing for gastrointestinal malignancies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110296,"accession_number":"0001104659-26-029588","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ArriVent to present preclinical data on firmonertinib and ARR-002 at AACR 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Firmonertinib preclinical data shows high potency and brain penetrance; supports ongoing Phase 3 in EGFR ex20ins NSCLC.","ARR-002 (MUC16/NaPi2b ADC) shows superior in vivo efficacy vs single-target ADCs in OVCAR-3 xenograft model.","ARR-002 demonstrates favorable tolerability in cynomolgus monkeys with reversible hematologic findings.","ARR-002 also selected for oral presentation at AACR Clinical Research Mini Symposium by Aarvik."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110295,"accession_number":"0001104659-26-024112","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ArriVent reports FY2025 net loss of $166.3M; cash of $312.8M funds into 3Q 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $312.8M as of Dec 31, 2025; expected to fund operations into 3Q 2027.","Net loss $166.3M in FY2025 vs $80.5M in FY2024; R&D expenses $153.4M (incl. one-time payment to Lepu).","Topline pivotal Phase 3 data for firmonertinib in first-line EGFR exon20ins NSCLC expected mid-2026.","Phase 3 ALPACCA study for firmonertinib in EGFR PACC mutant NSCLC dosed first patient in Dec 2025.","ADC lead ARR-217 in Phase 1 dose escalation; IND clearance received; first patient dosed March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126879,"accession_number":"0001104659-25-108839","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ArriVent reports Q3 net loss $130.8M; cash $305.4M funds into mid-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $130.8M for nine months ended Sep 30, 2025, up from $59.9M in 2024, driven by R&D spend including $40M upfront for ARR-217.","Cash and investments $305.4M as of Sep 30, 2025; expected to fund operations into mid-2027.","R&D expense $121.2M (incl. $40M upfront for ARR-217 license) vs $58.8M prior year; G&A $17.5M vs $11.8M.","Appointed Brent S. Rice as Chief Commercial Officer; Phase 1b firmonertinib data in EGFR PACC mutant NSCLC presented at WCLC.","Phase 3 ALPACCA trial for PACC mutant NSCLC first patient enrollment expected Q4 2025; topline FURVENT Phase 3 data in exon 20 insertion NSCLC projected early 2026."],"consensus_eps_estimate":-0.8051,"consensus_eps_actual":-3.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143669,"accession_number":"0001558370-25-011954","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ArriVent reports 16.0-month mPFS with firmonertinib in EGFR PACC NSCLC Phase 1b final analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS 16.0 months by BICR with firmonertinib 240 mg once daily in first-line EGFR PACC NSCLC.","Confirmed ORR 68.2% at 240 mg; median DOR 14.6 months by BICR; responses across multiple PACC mutation types.","CNS confirmed ORR 42.9% (6/14) with 35.7% CNS complete responses by BICR in evaluable patients.","First patient enrollment in global pivotal Phase 3 ALPACCA trial expected in H2 2025.","Safety profile maintained; most common TEAEs: diarrhea, hepatic enzyme elevation, rash; no new signals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143668,"accession_number":"0001558370-25-010974","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ArriVent Q2 2025 net loss $95.8M; firmonertinib PACC data positive; ADC ARR-217 dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $254.5M at June 30, plus $81.1M raised in July 2025 public offering; runway extended to mid-2027.","Net loss $95.8M for H1 2025 vs. $39.3M in H1 2024; R&D expense $89.0M including $40M one-time upfront to Lepu BioPharma.","Positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC; final data at WCLC September 2025.","First patient dosed in Phase 1 for ARR-217 (CDH17-targeted ADC) in gastrointestinal tumors by partner Lepu.","Top-line firmonertinib data from FURVENT Phase 3 for EGFR Exon20 insertion expected early 2026; PACC Phase 3 ALPACCA enrollment in 2H 2025."],"consensus_eps_estimate":-0.7178,"consensus_eps_actual":-2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143667,"accession_number":"0001104659-25-069169","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ArriVent projects topline phase 3 FURVENT data for firmonertinib in early 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topline firmonertinib monotherapy data from pivotal Phase 3 FURVENT study in 1L NSCLC EGFR exon20ins projected early 2026.","Primary endpoint is progression-free survival by blinded independent central review per RECIST 1.1.","Enrollment in the global FURVENT study completed in Q1 2025.","Firmonertinib previously received FDA Breakthrough Therapy Designation for this patient population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143666,"accession_number":"0001104659-25-065386","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ArriVent BioPharma prices $75M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$75M gross; priced 2,482,692 shares at $19.50 and 1,363,469 pre-funded warrants at $19.4999.","Underwriters have 30-day option to purchase up to 576,923 additional shares on same terms.","Proceeds to fund firmonertinib and other pipeline programs, plus working capital.","Expected close July 3, 2025; joint bookrunners: Goldman Sachs, Citigroup, Guggenheim Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161890,"accession_number":"0001104659-25-061375","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Positive Phase 1b firmonertinib data; 16.0 mo mPFS at 240 mg; global Phase 3 ALPACCA planned H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["16.0 months median PFS by BICR at 240 mg dose in first-line EGFR PACC mutant NSCLC; 68.2% confirmed ORR at 240 mg.","41% (7/17) confirmed CNS complete response; 53% CNS ORR in CNS-evaluable patients by BICR.","Safety consistent with prior data: no Grade 4/5 TRAEs, no discontinuations due to TRAEs; most common TRAEs diarrhea, elevated liver enzymes, rash.","Firmonertinib 240 mg selected for pivotal Phase 3; ALPACCA trial enrollment expected to start H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161889,"accession_number":"0001104659-25-061165","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ArriVent shareholders elect Yao and Peterson to board, ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 73.89% (25.2M shares) present at June 18 annual meeting.","Zhengbin Yao elected with 22.1M for vs 0.4M withheld; broker non-votes 2.6M.","Kristine Peterson elected with 21.9M for vs 0.6M withheld; broker non-votes 2.6M.","Ratification of PwC as FY2025 auditor: 25.0M for, 242 against, 167.5K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161888,"accession_number":"0001558370-25-007259","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ArriVent Q1 cash $205.5M, net loss $64.4M; Phase 3 enrollment completed for firmonertinib","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $205.5M as of March 31, 2025; net loss $64.4M (vs $17.4M YoY) due to $40M upfront payment to Lepu for ARR-217.","Completed enrollment in global pivotal Phase 3 FURVENT study for firmonertinib in first-line NSCLC EGFR exon20 insertion mutations.","Plans to provide update on firmonertinib in EGFR PACC mutant NSCLC in Q2 2025; topline Phase 3 data expected in 2025.","First IND for ARR-217 (CDH17 ADC) submitted in China; initial focus on colorectal, pancreatic, and other GI cancers.","Appointed Merdad Parsey, former Gilead CMO, to Board of Directors in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161887,"accession_number":"0001104659-25-039799","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ArriVent appoints Merdad Parsey to board; Carl Gordon not standing for re-election","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carl L. Gordon not standing for re-election at 2025 annual meeting (June 18); no disagreement with company.","Board expanded from 7 to 8; Merdad Parsey (former Gilead EVP/CMO) appointed effective April 28, 2025.","Parsey receives initial option grant of $352,000 and annual cash retainer of $45,000 plus $7,500 for committee service.","Directors Zhengbin Yao and Kristine Peterson reclassified from Class III to Class I to balance board classes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179946,"accession_number":"0001558370-25-002912","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ArriVent BioPharma dismisses KPMG, appoints PwC as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed KPMG on March 11, 2025; no disagreements on accounting principles or audit scope.","Previously reported material weaknesses in internal controls (manual journal entries, nonroutine transactions) were remediated as of Dec 31, 2024.","PricewaterhouseCoopers LLP appointed as independent auditor for fiscal year 2025.","No consultations with PwC prior to appointment regarding any contentious accounting matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179945,"accession_number":"0001558370-25-002002","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ArriVent reports FY2024 net loss $80.5M; cash $266.5M; Phase 3 trial enrollment achieved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $266.5M as of Dec 31, 2024; expected to fund operations into 2026.","Net loss $80.5M for FY2024 vs $69.3M in FY2023; R&D expense $79.0M.","Global pivotal Phase 3 FURVENT study for firmonertinib in EGFR exon20ins NSCLC reached target enrollment of 375 patients.","Selected next-generation ADC candidate ARR-002 for IND-enabling studies; in-licensed ARR-217 (MRG007) from Lepu Biopharma.","Plan to provide update on firmonertinib in EGFR PACC mutant NSCLC in H1 2025; top-line Phase 3 data expected in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179944,"accession_number":"0001104659-25-004967","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ArriVent licenses ADC MRG007 from Lepu Biopharma; upfront $47M, total potential $1.16B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive global rights outside Greater China for MRG007, a preclinical ADC targeting GI cancers.","Lepu Biopharma receives $47M in upfront and near-term milestones; eligible for up to $1.16B in total milestones plus tiered royalties.","First IND submission planned for first half 2025; initial focus on CRC, pancreatic, and other GI cancers.","ArriVent’s previously announced cash runway into 2026 remains unchanged despite upfront and R&D costs.","MRG007 showed robust antitumor activity and favorable therapeutic index in preclinical and IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196746,"accession_number":"0001558370-24-015622","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ArriVent reports Q3 2024 cash of $282.9M, net loss $59.9M; firmonertinib clinical progress highlighted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $282.9M as of Sept 30, 2024; expected to fund operations into 2026.","Net loss $59.9M for nine months ended Sept 30, 2024; R&D expenses $58.9M, G&A $11.8M.","Positive interim firmonertinib data in EGFR PACC mutant NSCLC presented at WCLC 2024 with CNS activity.","Phase 3 FURVENT trial top-line data for firmonertinib in EGFR exon 20 NSCLC expected in 2025.","Dose expansion for firmonertinib plus SHP2 inhibitor expected in Q4 2024; ADC candidate selection by early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213046,"accession_number":"0001104659-24-098059","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ArriVent: firmonertinib shows 81.8% ORR in EGFR PACC mutant NSCLC Phase 1b data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["81.8% ORR and 63.6% confirmed ORR by BICR at 240mg dose in first-line EGFR PACC mutant NSCLC.","46.2% confirmed CNS ORR (6/13) in patients with brain metastases at baseline.","Median duration of response not reached; 90.9% (20/22) of confirmed responders remain on study.","No Grade 4/5 TRAEs or treatment discontinuations due to TRAEs; safety consistent with prior data.","Data presented at WCLC 2024; ArriVent plans virtual webinar on September 9, 2024 at 4:30pm ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213045,"accession_number":"0001558370-24-012223","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ArriVent Q2 net loss $39.3M; cash $298.7M funds into 2026; firmonertinib data at WCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for six months ended June 30, 2024 was $39.3M, compared to $33.7M in prior year period.","Cash and cash equivalents $298.7M as of June 30, 2024; expected to fund operations into 2026.","R&D expenses $38.8M (up from $30.6M) due to increased headcount and firmonertinib clinical costs.","Interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC to be presented at WCLC presidential symposium on Sept 9, 2024.","Entered ADC collaboration with Alphamab to discover and develop novel ADCs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213044,"accession_number":"0001104659-24-078587","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K/A","filed_at":"2024-07-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ArriVent BioPharma appoints Dr. Hohneker to two board committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. John Hohneker appointed to Nominating and Corporate Governance Committee, effective July 3, 2024.","Also appointed to Compensation Committee of the Board, effective same date.","Amendment corrects omission from original May 16, 2024 8-K reporting his director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213043,"accession_number":"0001104659-24-078585","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K/A","filed_at":"2024-07-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ArriVent appoints Kristine Peterson to Board; she joins Compensation Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristine Peterson appointed as Class III director effective April 20, 2024, until 2027 annual meeting.","Appointed to Compensation Committee on July 3, 2024.","Received option grant with $352,500 fair value, vesting over three years; annual cash retainer of $45,000 prorated.","Peterson brings >30 years biopharma experience; former CEO of Valeritas, exec roles at J&J and BMS.","Currently on boards of Immunocore and Enanta; deemed independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232157,"accession_number":"0001104659-24-068503","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ArriVent BioPharma enters ADC collaboration with Alphamab; milestones up to $615.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration to discover, develop, and commercialize novel antibody drug conjugates (ADCs) for cancers.","Total upfront and milestone payments to Alphamab up to $615.5 million plus tiered sales royalties.","ArriVent gains exclusive rights to develop and commercialize ADCs outside greater China; Alphamab retains greater China rights.","Deal leverages Alphamab's proprietary linker-payload platform and glycan-conjugation technology.","ArriVent CEO Bing Yao cites potential to add multiple innovative ADC programs to pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232156,"accession_number":"0001104659-24-062528","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ArriVent BioPharma appoints John Hohneker, M.D., to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Hohneker, M.D., appointed to Board of Directors effective May 16, 2024 as Class II Director.","Dr. Hohneker most recently served as President & CEO of Anokion SA, and previously led R&D at Forma Therapeutics.","He held senior roles at Novartis for 14 years, including SVP and Global Head of Development, Immunology and Dermatology.","Current board seats: Carisma Therapeutics (CARM), Curis (CRIS), Sonata Therapeutics, and Trishula Therapeutics.","Received initial non-qualified stock option with fair value $352,500 vesting over three years; annual cash retainer $45,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232155,"accession_number":"0001558370-24-007196","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ArriVent Q1 net loss $17.4M; cash $317.4M; fully enrolled PACC cohort, initiated combo study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $317.4M as of March 31, 2024, expected to fund operations into 2026.","Net loss $17.4M for Q1 2024 vs $12.2M in Q1 2023; R&D expense $17.0M vs $10.2M.","Fully enrolled Phase 1b FURTHER trial for firmonertinib in NSCLC EGFR PACC mutations; proof-of-concept data expected in 2024.","Initiated Phase 1b combo study of firmonertinib and ICP-189 (SHP2 inhibitor) for EGFR classical mutation NSCLC.","Appointed Kristine Peterson to Board; presented preclinical AACR data showing broad activity across uncommon EGFR mutations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232158,"accession_number":"0001104659-24-049988","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ArriVent BioPharma appoints Kristine Peterson to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective April 20, 2024; Peterson to serve as Class III Director until 2027 annual meeting.","Peterson brings over 30 years' experience; former CEO of Valeritas and executive at J&J and Bristol-Myers Squibb.","Receives non‑employee director compensation: annual cash retainer of $45,000 and stock option with $235,000 grant date fair value.","Option vests one year from grant date (April 22, 2024); no related transactions or family relations disclosed.","Board determined she is independent under Nasdaq rules; no committee assignments yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250422,"accession_number":"0001104659-24-040532","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrivent Biopharma reports FY 2023 net loss of $69.3M; cash runway into 2026 after $201M IPO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $64.9M in 2023, up from $30.4M in 2022 on increased furmonertinib trial spending.","Net loss $69.3M vs $37.0M in prior year; cash & marketable securities $150.4M at Dec 31, 2023.","Completed $201M IPO in Jan 2024; management expects operations funded into 2026.","FDA granted Breakthrough Therapy Designation for furmonertinib in NSCLC with EGFR exon 20 ins.","Proof-of-concept data for furmonertinib in PACC mutations expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250421,"accession_number":"0001104659-24-008228","cik":1868279,"company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"ArriVent BioPharma completes IPO of 9.7M shares at $18, raising ~$175M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 9,722,222 shares of common stock at $18.00 per share closed January 30, 2024.","Gross proceeds to the company were approximately $175.0 million before expenses.","Amended and restated certificate of incorporation and bylaws filed and effective upon IPO closing.","Common stock trades on Nasdaq under ticker AVBP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1255194285.8973427,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}